Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

NSCLC Meta-analysis Collaborative Group, Sarah Burdett, Larysa H M Rydzewska, Jayne F Tierney, Anne Auperin, Cécile Le Pechoux, Thierry Le Chevalier, Jean-Pierre Pignon, Rodrigo Arriagada, David H Johnson, Jan van Meerbeeck, Mahesh K B Parmar, Richard J Stephens, Lesley A Stewart, Rodrigo Arriagada, Anne Auperin, Sarah Burdett, David H Johnson, Thierry Le Chevalier, Cécile Le Pechoux, Mahesh K B Parmar, Jean-Pierre Pignon, Larysa H M Rydzewska, Richard J Stephens, Lesley A Stewart, Jayne F Tierney, Jan van Meerbeeck, Paul A Bunn, Bertrand Dautzenberg, David Gilligan, Harry J M Groen, Aija H Knuuttila, Katherine M Pisters, Rafael Rosell, Jack Roth, Giorgio Scagliotti, Masahiro Tsuboi, David A Waller, Virginie Westeel, Yi-Long Wu, Xue-Ning Yang, NSCLC Meta-analysis Collaborative Group, Sarah Burdett, Larysa H M Rydzewska, Jayne F Tierney, Anne Auperin, Cécile Le Pechoux, Thierry Le Chevalier, Jean-Pierre Pignon, Rodrigo Arriagada, David H Johnson, Jan van Meerbeeck, Mahesh K B Parmar, Richard J Stephens, Lesley A Stewart, Rodrigo Arriagada, Anne Auperin, Sarah Burdett, David H Johnson, Thierry Le Chevalier, Cécile Le Pechoux, Mahesh K B Parmar, Jean-Pierre Pignon, Larysa H M Rydzewska, Richard J Stephens, Lesley A Stewart, Jayne F Tierney, Jan van Meerbeeck, Paul A Bunn, Bertrand Dautzenberg, David Gilligan, Harry J M Groen, Aija H Knuuttila, Katherine M Pisters, Rafael Rosell, Jack Roth, Giorgio Scagliotti, Masahiro Tsuboi, David A Waller, Virginie Westeel, Yi-Long Wu, Xue-Ning Yang

Abstract

Background: Individual participant data meta-analyses of postoperative chemotherapy have shown improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to do a systematic review and individual participant data meta-analysis to establish the effect of preoperative chemotherapy for patients with resectable NSCLC.

Methods: We systematically searched for trials that started after January, 1965. Updated individual participant data were centrally collected, checked, and analysed. Results from individual randomised controlled trials (both published and unpublished) were combined using a two-stage fixed-effect model. Our primary outcome, overall survival, was defined as the time from randomisation until death (any cause), with living patients censored on the date of last follow-up. Secondary outcomes were recurrence-free survival, time to locoregional and distant recurrence, cause-specific survival, complete and overall resection rates, and postoperative mortality. Prespecified analyses explored any variation in effect by trial and patient characteristics. All analyses were by intention to treat.

Findings: Analyses of 15 randomised controlled trials (2385 patients) showed a significant benefit of preoperative chemotherapy on survival (hazard ratio [HR] 0·87, 95% CI 0·78-0·96, p=0·007), a 13% reduction in the relative risk of death (no evidence of a difference between trials; p=0·18, I(2)=25%). This finding represents an absolute survival improvement of 5% at 5 years, from 40% to 45%. There was no clear evidence of a difference in the effect on survival by chemotherapy regimen or scheduling, number of drugs, platinum agent used, or whether postoperative radiotherapy was given. There was no clear evidence that particular types of patient defined by age, sex, performance status, histology, or clinical stage benefited more or less from preoperative chemotherapy. Recurrence-free survival (HR 0·85, 95% CI 0·76-0·94, p=0·002) and time to distant recurrence (0·69, 0·58-0·82, p<0·0001) results were both significantly in favour of preoperative chemotherapy although most patients included were stage IB-IIIA. Results for time to locoregional recurrence (0·88, 0·73-1·07, p=0·20), although in favour of preoperative chemotherapy, were not statistically significant.

Interpretation: Findings, which are based on 92% of all patients who were randomised, and mainly stage IB-IIIA, show preoperative chemotherapy significantly improves overall survival, time to distant recurrence, and recurrence-free survival in resectable NSCLC. The findings suggest this is a valid treatment option for most of these patients. Toxic effects could not be assessed.

Funding: Medical Research Council UK.

Copyright © 2014 NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Effect of preoperative chemotherapy on survival Each square denotes the HR for that trial comparison with the horizontal lines showing the 95% and 99% CIs. The size of the square is directly proportional to the amount of information contributed by the trial. The black diamond gives the pooled HR from the fixed effect model; the centre of this diamond denotes the HR and the extremities the 95% CI. O–E=observed minus expected. HR=hazard ratio. MIP=mitomycin, ifosphamide, cisplatin. SWOG=South West Oncology Group. JCOG=Japanese Cancer Oncology Group. MRC=Medical Research Council. BLT=Big Lung Trial. ChEST=Chemotherapy for Early Stages Trial. NATCH=Neoadjuvant/Adjuvant Trial of Chemotherapy. df=degrees of freedom. *Number of events/number entered.
Figure 2
Figure 2
Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to survival
Figure 3
Figure 3
Forest plot of the interactions between the effect of preoperative chemotherapy on survival and covariates The circles represent (fixed effect) meta-analyses of the HRs representing the interactions between the effect of chemotherapy and patient characteristics; the horizontal line shows the 95% CI. HR=hazard ratio.
Figure 4
Figure 4
Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to distant and locoregional recurrence and recurrence-free survival Analyses of recurrence outcomes were calculated from a landmark time of 6 months from the date of randomisation; for this reason time on the x-axis starts at 6 months.

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
    1. American Cancer Society . Cancer facts and figures 2007. American Cancer Society; Atlanta: 2007.
    1. Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest. 2003;123:2096–2103.
    1. NSCLC Meta-analyses Collaborative Group Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–1277.
    1. Berghmans T, Paesmans M, Meert AP. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer. 2005;49:13–23.
    1. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Role of preoperative chemotherapy for non-small-cell lung cancer: a meta-analysis. Lung Cancer. 2006;54:325–329.
    1. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006;1:611–621.
    1. Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009;4:1380–1388.
    1. Song WA, Zhou NK, Wang W. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol. 2010;5:510–516.
    1. Lefebvre C, Manheimer E, Glanville J, the Cochrane Information Retrieval Methods Group . Searching for studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons Ltd; Chichester: 2008. pp. 95–150.
    1. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med. 1995;14:2057–2079.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.97.
    1. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–5067.
    1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371.
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–481.
    1. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346.
    1. Fisher DJ, Copas AJ, Tierney JF, Parmar MKB. A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J Clin Epidemiol. 2011;64:949–967.
    1. Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 1993;341:418–422.
    1. Dautzenberg B, Benichou J, Allard P. Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma. Results from a randomized phase II trial. Cancer. 1990;65:2435–2441.
    1. Roth JA, Fossella F, Komaki R. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–680.
    1. Rosell R, Gómez-Codina J, Camps C. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–158.
    1. Depierre A, Milleron B, Moro-Sibilot D, the French Thoracic Cooperative Group Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247–253.
    1. Nagai K, Tsuchiya R, Mori T, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209) J Thorac Cardiovasc Surg. 2003;125:254–260.
    1. Splinter TA, van Putten JW, Meuzalaar J, Smit EF, Kho GS, Groen HJ. Randomized multicenter phase II study of chemotherapy followed by surgery versus surgery alone in stage I and II non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol. 2000;19:495. (abstr 1937).
    1. Mattson KV, Abratt RP, ten Velde G, Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol. 2003;14:116–122.
    1. Waller D, Peake MD, Stephens RJ. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173–182.
    1. Gilligan D, Nicolson M, Smith I. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929–1937.
    1. Pisters KM, Vallières E, Crowley JJ. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010;28:1843–1849.
    1. Wu Y-L, Gu L-J, Weng Y-M, Feng W-N, Cheng C. Neo-adjuvant chemotherapy with docetaxel plus carboplatin for non-small cell lung cancer. Ann Oncol. 2002;13(suppl 5):140. (abstr 510P).
    1. Yang X, Wu Y, Gu L. A randomized trial comparing neoadjuvant gemcitabine plus carboplatin or cisplatin followed by surgery with surgery alone in Clinical Stage IIIA non-small-cell lung cancer (NSCLC) Lung Cancer. 2005;49:S288. (abstr P-645).
    1. Scagliotti GV, Pastorino U, Vansteenkiste JF. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30:172–178.
    1. Felip E, Rosell R, Maestre JA, the Spanish Lung Cancer Group Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28:3138–3145.
    1. de Boer RH, Smith IE, Pastorino U. Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial. Br J Cancer. 1999;79:1514–1518.
    1. Yi X, Zhang R, Ding J, Gao W, Ma Q, Zhong C. A clinicopathologic study on neoadjuvant chemotherapy in the treatment of non-small-cell lung cancer. Zhongguo Fei Ai Za Zhi. 2003;6:124–128. (in Chinese).
    1. Sorensen JB, Riska H, Ravn J. Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIA/T3. Proc Am Soc Clin Oncol. 2005;23:7146.
    1. Chaudhri N. Randomized phase III trial of surgery alone or surgery plus preoperative gemcitabine-cisplatin in clinical early stages of non-small cell lung cancer. (accessed Nov 6, 2013).
    1. Bunn P. Phase III randomized comparison of pre- and postoperative chemotherapy with VP-16/CBDCA vs surgery alone in patients with operable nonsmall cell carcinoma of the lung. (accessed Nov 6, 2013).
    1. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–2834.
    1. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992;53:992–998.
    1. Yang X-N, Cheng G, Ben X-S. Survival study of neoadjuvant versus adjuvant chemotherapy with docetaxel combined carboplatin in resectable stage IB to IIIA non-small cell lung cancer. ASCO Annual Meeting. 2013:7537.
    1. Westeel V, Quoix E, Puyraveau M, the Intergroupe Francophone de Cancérologie Thoracique A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial) Eur J Cancer. 2013;49:2654–2664.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅